Abstract: Preemption in wireless may be provided. Access Category (AC) parameters may be received for a preemption AC within a plurality of ACs. The preemption AC parameters may comprise a Contention Window maximum (CWmax) comprising a first predetermined value and a preemption Arbitrary Interframe Space Number (AIFSN) of less than or equal to a second predetermined value. AC parameters for others of the plurality of ACs may be received wherein a non-preemption AIFSN associated with any of the others of the plurality of ACs is greater than a sum of the first predetermined value the second predetermined value. Preemption for traffic in the preemption AC may be allowed.

Abstract: The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.

Abstract: The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants. In some aspects, pharmaceutical composition is formulated for subcutaneous delivery. In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering the pharmaceutical composition.

Abstract: The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.

Abstract: The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants. In some aspects, pharmaceutical composition is formulated for subcutaneous delivery. In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering the pharmaceutical composition.

Abstract: A method for performing a dynamic spatial search for points of interest proximal to a path of travel of a moving user. As the user moves along a path, a search is regularly conducted to provide updated information about points of interest for the user. The method includes automatically detecting a position of the user. One or more attributes of the user's movement and/or of a vicinity around the position of the user are detected. To provide the updated search information a new search region is determined based on the user's position and the one or more detected attributes. The new search region is compared to the previously determined search region to determine an overlap region that the two have in common. Search results from the overlap region are reused as part of point of interest search results for the current search region. New point of interest search results are calculated only for a portion of the new search region outside of the overlap region.